A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Launched by KISSEI PHARMACEUTICAL CO., LTD. · May 8, 2013
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients age 20 or older, regardless of gender.
- • Receiving stable maintenance hemodialysis 3 times a week.
- • Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.
- Exclusion Criteria:
- • Patients having history of a pronounced brain / cardiovascular disorder.
- • Patients having severe gastrointestinal disorders.
- • Patients having severe hepatic disorders.
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. is a leading Japanese pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. With a strong focus on specialty pharmaceuticals, Kissei leverages advanced technologies and rigorous clinical research to create effective treatments in areas such as urology, nephrology, and diabetes management. Committed to enhancing patient outcomes, Kissei collaborates with healthcare professionals and research institutions worldwide, ensuring a comprehensive approach to drug development that aligns with global health standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials